

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 3 December 2018 – On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2018.

Under the programme initiated 5 November 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 3.2 billion in the period from 6 November 2018 to 30 January 2019.

Since the announcement as of 26 November 2018, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,845,000		829,187,603
26 November 2018	206,000	303.07	62,431,718
27 November 2018	210,000	301.75	63,366,706
28 November 2018	200,000	299.74	59,947,993
29 November 2018	210,000	301.91	63,401,142
30 November 2018	200,000	305.18	61,036,951
Accumulated under the programme	3,871,000		1,139,372,113

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 52,971,648 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,450,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2018. As of 30 November 2018, Novo Nordisk has since 1 February 2018 repurchased a total of 43,057,630 B shares at an average share price of DKK 300.68 per B share equal to a transaction value of DKK 12,946,438,984.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 240 9429	kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Anders Mikkelsen	+45 3079 4461	armk@novonordisk.com
Valdemar Borum Svarrer	+45 3079 0301	jvls@novonordisk.com
Kristoffer Due Berg	+45 3079 2849	krdb@novonordisk.com